Skip to main content

Hypothyroidism in the Elderly: Pathophysiology, Diagnosis and Treatment

Drugs & Aging volume 22, pages 23–38 (2005)Cite this article

Abstract

Some degree of hypothyroidism is common in the elderly. It affects 5–20% of women and 3–8% of men. The occurrence varies with genetics with a high prevalence in Caucasians, and the disease is more common in populations with a high iodine intake.

The common causes of hypothyroidism are autoimmune destruction of the thyroid gland and previous thyroid surgery or radioiodine therapy. Various types of medication, including amiodarone, cytokines and lithium, often induce hypothyroidism.

Symptoms may be atypical and measurement of serum thyroid-stimulating hormone (TSH) levels should be part of biochemical testing for undiagnosed medical conditions in elderly subjects. The finding of an elevated serum TSH level should be confirmed by repeated testing and supplemented with measurements of serum levels of thyroxine (T4) and thyroid peroxidase antibodies to verify, quantify and subclassify the abnormality.

The recommended and appropriate replacement therapy for hypothyroidism is levothyroxine sodium. The initial replacement dose should be low if heart disease is suspected. Because of the long half-life of levothyroxine sodium small dosage adjustments may be performed by adding or withdrawing a tablet once or twice weekly. Levothyroxine sodium is only partly absorbed after oral ingestion, and food, minerals, drugs and tablet composition influence absorption.

Studies performed a few years ago suggested that a combination of levothyroxine sodium and liothyronine may improve clinical results, but recent more comprehensive studies have not supported this hypothesis. Accordingly, liothyronine replacement is not documented to be of benefit. If liothyronine is added to replacement, the liothyronine dose should be kept low, within the physiological range and, preferably be administered twice daily.

Thyroid hormone therapy has no beneficial effect above placebo in elderly individuals with normal serum TSH levels and T4 levels. The major risk of levothyroxine sodium therapy is over-replacement, with anxiety, muscle wasting, osteoporosis and atrial fibrillation as adverse effects.

Subclinical hypothyroidism with elevated serum TSH levels but T4 levels within the laboratory reference range is a mild variant of overt hypothyroidism. Patients with subclinical hypothyroidism should be informed about the disease and offered the possibility of replacement. Only some patients treated for subclinical hypothyroidism will feel better after therapy.

In elderly patients on replacement therapy, care should include estimation of serum TSH level once or twice a year, with small dosage adjustments of levothyroxine sodium to keep serum TSH level within the normal range.

This is a preview of subscription content, access via your institution.

Access options

Buy single article

Instant access to the full article PDF.

49,54 €

Price includes VAT (Finland)
Tax calculation will be finalised during checkout.

Fig. 1
Table I
Table II
Fig. 2
Table III

References

  1. Bulow Pedersen I, Knudsen N, Jorgensen T, et al. Large differences in incidences of overt hyper- and hypothyroidism associated with a small difference in iodine intake: a prospective comparative register-based population survey. J Clin Endocrinol Metab 2002; 87: 4462–9

    PubMed  Google Scholar 

  2. Bauer DC, Ettinger B, Browner WS. Thyroid functions and serum lipids in older women: a population-based study. Am J Med 1998 Jun; 104(6): 546–51

    PubMed  CAS  Google Scholar 

  3. Hollowell JG, Staehling NW, Flanders WD, et al. Serum TSH, T(4), and thyroid antibodies in the United States population (1988 to 1994): National Health and Nutrition Examination Survey (NHANES III). J Clin Endocrinol Metab 2002; 87: 489–99

    PubMed  CAS  Google Scholar 

  4. Flynn RW, Macdonald TM, Morris AD, et al. The thyroid epidemiology, audit, and research study: thyroid dysfunction in the general population. J Clin Endocrinol Metab 2004; 89: 3879–84

    PubMed  CAS  Google Scholar 

  5. Laurberg P, Pedersen KM, Hreidarsson A, et al. Iodine intake and the pattern of thyroid disorders: a comparative epidemiological study of thyroid abnormalities in the elderly in Iceland and in Jutland, Denmark. J Clin Endocrinol Metab 1998; 83: 765–9

    PubMed  CAS  Google Scholar 

  6. Okayasu I, Hatakeyama S, Tanaka Y, et al. Is focal chronic autoimmune thyroiditis an age-related disease? Differences in incidence and severity between Japanese and British. J Pathol 1991; 163: 257–64

    PubMed  CAS  Google Scholar 

  7. Okayasu I, Hara Y, Nakamura K, et al. Racial and age-related differences in incidence and severity of focal autoimmune thyroiditis. Am J Clin Pathol 1994; 101: 698–702

    PubMed  CAS  Google Scholar 

  8. Pedersen IB, Knudsen N, Jorgensen T, et al. Thyroid peroxidase and thyroglobulin autoantibodies in a large survey of populations with mild and moderate iodine deficiency. Clin Endocrinol (Oxf) 2003; 58: 36–42

    Google Scholar 

  9. Weetman AP. Autoimmune thyroid disease: propagation and progression. Eur J Endocrinol 2003; 148: 1–9

    PubMed  CAS  Google Scholar 

  10. Rapoport B, McLachlan SM. Thyroid autoimmunity. J Clin Invest 2001; 108: 1253–9

    PubMed  PubMed Central  CAS  Google Scholar 

  11. Abreau CM, Vagenakis AG, Roti E, et al. Clinical evaluation of a hemagglutination method for microsomal and thyroglobulin antibodies in autoimmune thyroid disease. Ann Clin Lab Sci 1977; 7: 73–8

    PubMed  CAS  Google Scholar 

  12. Arai T, Kurashima C, Utsuyama M, et al. Measurement of anti-thyroglobulin and anti-thyroid peroxidase antibodies using highly sensitive radioimmunoassay: an effective method for detecting asymptomatic focal lymphocytic thyroiditis in the elderly. Endocr J 2000; 47: 575–82

    PubMed  CAS  Google Scholar 

  13. Pedersen IB, Knudsen N, Perrild H, et al. TSH-receptor antibody measurement for differentiation of hyperthyroidism into Graves’ disease and multinodular toxic goitre: a comparison of two competitive binding assays. Clin Endocrinol 2001; 55: 381–90

    CAS  Google Scholar 

  14. Brix TH, Kyvik KO, Hegedus L. A population-based study of chronic autoimmune hypothyroidism in Danish twins. J Clin Endocrinol Metab 2000; 85: 536–9

    PubMed  CAS  Google Scholar 

  15. Vestergaard P, Rejnmark L, Weeke J, et al. Smoking as a risk factor for Graves’ disease, toxic nodular goiter, and autoimmune hypothyroidism. Thyroid 2002; 12: 69–75

    PubMed  Google Scholar 

  16. Knudsen N, Bulow Pedersen I, Laurberg P, et al. High occurrence of thyroid multinodularity and low occurrence of hypothyroidism among tobacco smokers in a large population survey. J Endocrinol 2002; 175: 571–6

    PubMed  CAS  Google Scholar 

  17. Ando T, Davies TF. Clinical Review 160: postpartum autoimmune thyroid disease: the potential role of fetal microchimerism. J Clin Endocrinol Metab 2003; 88: 2965–71

    PubMed  CAS  Google Scholar 

  18. International Council for the Control of Iodine Deficiency Disorders, The United Nations Children’s Fund, World Health Organization 2001 Assessment of iodine deficiency disorders and monitoring their elimination. 2nd ed. Geneva: World Health Organization, 2001

    Google Scholar 

  19. Andersen S, Pedersen KM, Pedersen IB, et al. Variations in urinary iodine excretion and thyroid function: a 1-year study in healthy men. Eur J Endocrinol 2001; 144: 461–5

    PubMed  CAS  Google Scholar 

  20. Jahreis G, Hausmann W, Kiessling G, et al. Bioavailability of iodine from normal diets rich in dairy products: results of balance studies in women. Exp Clin Endocrinol Diabetes 2001; 109: 163–7

    PubMed  CAS  Google Scholar 

  21. Laurberg P, Bulow Pedersen I, Knudsen N, et al. Environmental iodine intake affects the type of nonmalignant thyroid disease. Thyroid 2001; 11: 457–69

    PubMed  CAS  Google Scholar 

  22. Braverman LE. Iodine and the thyroid: 33 years of study. Thyroid 1994; 4: 351–6

    PubMed  CAS  Google Scholar 

  23. Sridama V, McCormick M, Kaplan EL, et al. Long-term follow-up study of compensated low-dose 131I therapy for Graves’ disease. N Engl J Med 1984; 311: 426–32

    PubMed  CAS  Google Scholar 

  24. Vestergaard H, Laurberg P. Radioiodine treatment of recurrent hyperthyroidism in patients previously treated for Graves’ disease by subtotal thyroidectomy. J Intern Med 1992; 231: 13–7

    PubMed  CAS  Google Scholar 

  25. Laurberg P, Hansen PEB, Iversen E, et al. Goitre size and outcome of medical treatment of Graves’ disease. Acta Endocrinol (Copenh) 1986; 111: 39–43

    CAS  Google Scholar 

  26. Delbridge L, Guinea AI, Reeve TS. Total thyroidectomy for bilateral benign multinodular goiter: effect of changing practice. Arch Surg 1999; 134: 1389–93

    PubMed  CAS  Google Scholar 

  27. Thomusch O, Sekulla C, Dralle H. Is primary total thyroidectomy justified in benign multinodular goiter? Results of a prospective quality assurance study of 45 hospitals offering different levels of care [in German]. Chirurg 2003; 74: 437–43

    PubMed  CAS  Google Scholar 

  28. Friguglietti CU, Lin CS, Kulcsar MA. Total thyroidectomy for benign thyroid disease. Laryngoscope 2003; 113: 1820–6

    PubMed  Google Scholar 

  29. Martino E, Bartalena L, Bogazzi F, et al. The effects of amiodarone on the thyroid. Endocr Rev 2001; 22: 240–54

    PubMed  CAS  Google Scholar 

  30. Wiersinga WM. Amiodarone and the thyroid: handbook of experimental pharmacology. Vol. 128. In: Weetman AP, Grossman A, editors. Pharmacotherapeutics of the thyroid gland. Heidelberg: Springer-Verlag 1997: 225–87

    Google Scholar 

  31. Prummel MF, Laurberg P. Interferon-alpha and autoimmune thyroid disease. Thyroid 2003; 13: 547–51

    PubMed  CAS  Google Scholar 

  32. Lazarus JH. The effects of lithium therapy on thyroid and thyrotropin-releasing hormone. Thyroid 1998; 8: 909–13

    PubMed  CAS  Google Scholar 

  33. Martino E, Safran M, Aghini-Lombardi F, et al. Environmental iodine intake and thyroid dysfunction during chronic amiodarone therapy. Ann Intern Med 1984; 101: 28–34

    PubMed  CAS  Google Scholar 

  34. Laurberg P, Jacobsen PE, Hoeck HC, et al. Growth hormone and thyroid function: is secondary thyroid failure underdiagnosed in growth hormone deficient patients? Thyroidology Clin Exp 1994; 6: 73–9

    CAS  Google Scholar 

  35. Gomez N, Gomez JM, Orti A, et al. Transient hypothyroidism after iodine-131 therapy for Graves’ disease. J Nucl Med 1995; 36: 1539–42

    PubMed  CAS  Google Scholar 

  36. Toft AD, Irvine WJ, Mclntosh D, et al. Temporary hypothyroidism after surgical treatment of thyrotoxicosis. Lancet 1976; II: 817–8

    Google Scholar 

  37. Knudsen N, Bulow Pedersen I, Joergensen T, et al. Comparative study of thyroid function and types of thyroid dysfunction in two areas in Denmark with slightly different iodine status. Eur J Endocrinol 2000; 143: 485–91

    PubMed  CAS  Google Scholar 

  38. Canaris GJ, Manowitz NR, Mayor G, et al. The Colorado thyroid disease prevalence study. Arch Intern Med 2000; 160: 526–34

    PubMed  CAS  Google Scholar 

  39. Pollock MA, Sturrock A, Marshall K, et al. Thyroxine treatment in patients with symptoms of hypothyroidism but thyroid function tests within the reference range: randomised double blind placebo controlled crossover trial. BMJ 2001; 323: 891–5

    PubMed  PubMed Central  CAS  Google Scholar 

  40. Alexopoulou O, Beguin C, De Nayer P, et al. Clinical and hormonal characteristics of central hypothyroidism at diagnosis and during follow-up in adult patients. Eur J Endocrinol 2004; 150: 1–8

    PubMed  CAS  Google Scholar 

  41. Faglia G, Bitensky L, Pinchera A, et al. Thyrotropin secretion in patients with central hypothyroidism: evidence for reduced biological activity of immunoreactive thyrotropin. J Clin Endocrinol Metab 1979; 48: 989–98

    PubMed  CAS  Google Scholar 

  42. Baloch Z, Carayon P, Conte-Devolx B, et al. Laboratory medicine practice guidelines: laboratory support for the diagnosis and monitoring of thyroid disease. Thyroid 2003; 13: 3–126

    PubMed  Google Scholar 

  43. Andersen S, Pedersen KM, Bruun NH, et al. Narrow individual variations in serum T4 and T3 in normal subjects: a clue to the understanding of subclinical thyroid disease. J Clin Endocrinol Metab 2002; 87: 1068–72

    PubMed  CAS  Google Scholar 

  44. Wang R, Nelson JC, Weiss RM, et al. Accuracy of free thyroxine measurements across natural ranges of thyroxine binding to serum proteins. Thyroid 2000; 10: 31–9

    PubMed  CAS  Google Scholar 

  45. Spencer CA, LoPresti JS, Patel A, et al. Applications of a new chemiluminometric thyrotropin assay to subnormal measurement. J Clin Endocrinol Metab 1990; 70: 453–60

    PubMed  CAS  Google Scholar 

  46. Carr D, McLeod DT, Parry G, et al. Fine adjustment of thyroxine replacement dosage: comparison of the thyrotrophin releasing hormone test using a sensitive thyrotrophin assay with measurement of free thyroid hormones and clinical assessment. Clin Endocrinol 1988; 28: 325–33

    CAS  Google Scholar 

  47. Zulewski H, Muller B, Exer P, et al. Estimation of tissuehypothyroidism by a new clinical score: evaluation of patients with various grades of hypothyroidism and controls. J Clin Endocrinol Metab 1997; 82: 771–6

    PubMed  CAS  Google Scholar 

  48. Laurberg P. Thyroxine and 3,5,3′-triiodothyronine content of thyroglobulin in thyroid needle aspirates in hyperthyroidism and hypothyroidism. J Clin Endocrinol Metab 1987; 64: 969–74

    PubMed  CAS  Google Scholar 

  49. Bianco AC, Salvatore D, Gereben B, et al. Biochemistry, cellular and molecular biology, and physiological roles of the iodothyronine selenodeiodinases. Endocr Rev 2002; 23: 38–89

    PubMed  CAS  Google Scholar 

  50. Huber G, Staub JJ, Meier C, et al. Prospective study of the spontaneous course of subclinical hypothyroidism: prognostic value of thyrotropin, thyroid reserve, and thyroid antibodies. J Clin Endocrinol Metab 2002; 87: 3221–6

    PubMed  CAS  Google Scholar 

  51. Laurberg P, Bulow Pedersen I, Pedersen KM, et al. Low incidence rate of overt hypothyroidism compared with hyperthyroidism in an area with moderately low iodine intake. Thyroid 1999; 9: 33–8

    PubMed  CAS  Google Scholar 

  52. Gregerman RI, Gaffney GW, Shock NW, et al. Thyroxine turnover in euthyroid man with special reference to changes with age. J Clin Invest 1962; 41(11): 2065–74

    PubMed  PubMed Central  CAS  Google Scholar 

  53. Fish LH, Schwartz HL, Cavanaugh J, et al. Replacement dose, metabolism, and bioavailability of levothyroxine in the treatment of hypothyroidism: role of triiodothyronine in pituitary feedback in humans. N Engl J Med 1987; 316: 764–70

    PubMed  CAS  Google Scholar 

  54. Aizawa T, Koizumi Y, Yamada T, et al. Difference in pituitary-thyroid feedback regulation in hypothyroid patients, depending on the severity of hypothyroidism. J Clin Endocrinol Metab 1978; 47: 560–5

    PubMed  CAS  Google Scholar 

  55. Myerowitz PD, Kamienski RW, Swanson DK, et al. Diagnosis and management of the hypothyroid patient with chest pain. J Thorac Cardiovasc Surg 1983; 86: 57–60

    PubMed  CAS  Google Scholar 

  56. Sherman SI, Ladenson PW. Percutaneous transluminal coronary angioplasty in hypothyroidism. Am J Med 1991; 90: 367–70

    PubMed  CAS  Google Scholar 

  57. Wennlund A. Variation in serum levels of T3, T4, FT4 and TSH during thyroxine replacement therapy. Acta Endocrinol 1986; 113: 47–9

    PubMed  CAS  Google Scholar 

  58. Ain KB, Pucino F, Shiver TM, et al. Thyroid hormone levels affected by time of blood sampling in thyroxine-treated patients. Thyroid 1993; 3: 81–5

    PubMed  CAS  Google Scholar 

  59. Grebe SK, Cooke RR, Ford HC, et al. Treatment of hypothyroidism with once weekly thyroxine. J Clin Endocrinol Metab 1997; 82: 870–5

    PubMed  CAS  Google Scholar 

  60. Taylor J, Williams BO, Frater J, et al. Twice-weekly dosing for thyroxine replacement in elderly patients with primary hypothyroidism. J Int Med Res 1994; 22: 273–7

    PubMed  CAS  Google Scholar 

  61. Hays MT. Localization of human thyroxine absorption. Thyroid 1991; 1: 241–8

    PubMed  CAS  Google Scholar 

  62. Wenzel KW, Kirschsieper HE. Aspects of the absorption of oral L-thyroxine in normal man. Metabolism 1977; 26: 1–8

    PubMed  CAS  Google Scholar 

  63. Campbell NR, Hasinoff BB, Stalts H, et al. Ferrous sulfate reduces thyroxine efficacy in patients with hypothyroidism. Ann Intern Med 1992; 117: 1010–3

    PubMed  CAS  Google Scholar 

  64. Singh N, Weisler SL, Hershman JM. The acute effect of calcium carbonate on the intestinal absorption of levothyroxine. Thyroid 2001; 11: 967–71

    PubMed  CAS  Google Scholar 

  65. Liel Y, Sperber AD, Shany S. Nonspecific intestinal adsorption of levothyroxine by aluminum hydroxide. Am J Med 1994; 97: 363–5

    PubMed  CAS  Google Scholar 

  66. Sherman SI, Tielens ET, Ladenson PW. Sucralfate causes malabsorption of L-thyroxine. Am J Med 1994; 96: 531–5

    PubMed  CAS  Google Scholar 

  67. Northcutt RC, Stiel JN, Hollifield JW, et al. The influence of cholestyramine on thyroxine absorption. JAMA 1969; 208: 1857–61

    PubMed  CAS  Google Scholar 

  68. Siraj ES, Gupta MK, Reddy SS. Raloxifene causing malabsorption of levothyroxine. Arch Intern Med 2003; 163: 1367–70

    PubMed  Google Scholar 

  69. Hagag P, Nissenbaum H, Weiss M. Role of colestipol in the treatment of hyperthyroidism. J Endocrinol Invest 1998; 21: 725–31

    PubMed  CAS  Google Scholar 

  70. Bevan JS, Munro JF. Thyroxine malabsorption following intestinal bypass surgery. Int J Obes 1986; 10: 245–6

    PubMed  CAS  Google Scholar 

  71. De Luca F, Arrigo T, Pandullo E, et al. Changes in thyroid function tests induced by 2 month carbamazepine treatment in L-thyroxine-substituted hypothyroid children. Eur J Pediatr 1986; 145: 77–9

    PubMed  Google Scholar 

  72. Faber J, Lumholtz IB, Kirkegaard C, et al. The effects of Phenytoin (diphenylhydantoin) on the extrathyroidal turnover of thyroxine, 3,5,3′-triiodothyronine, 3,3′,5′-triiodothyronine, and 3′,5′-diiodothyronine in man. J Clin Endocrinol Metab 1985; 61: 1093–9

    PubMed  CAS  Google Scholar 

  73. Nolan SR, Self TH, Norwood JM. Interaction between rifampin and levothyroxine. South Med J 1999; 92: 529–31

    PubMed  CAS  Google Scholar 

  74. Arafah BM. Increased need for thyroxine in women with hypothyroidism during estrogen therapy. N Engl J Med 2001 Jun 7; 344(23): 1743–9

    PubMed  CAS  Google Scholar 

  75. Sawin CT, Herman T, Molitch ME, et al. Aging and the thyroid. Decreased requirement for thyroid hormone in older hypothyroid patients. Am J Med 1983; 75: 206–9

    PubMed  CAS  Google Scholar 

  76. Arafah BM. Decreased levothyroxine requirement in women with hypothyroidism during androgen therapy for breast cancer. Ann Intern Med 1994; 121: 247–51

    PubMed  CAS  Google Scholar 

  77. Cunningham JJ, Barzel US. Lean body mass is a predictor of the daily requirement for thyroid hormone in older men and women. J Am Geriate Soc 1984; 32: 204–7

    CAS  Google Scholar 

  78. Braverman LE. Levothyroxine: brand yes, generic no. J Clin Endocrinol Metab 1995; 80: 2876–7

    Google Scholar 

  79. Olveira G, Almaraz MC, Soriguer F, et al. Altered bioavailability due to changes in the formulation of a commercial preparation of levothyroxine in patients with differentiated thyroid carcinoma. Clin Endocrinol 1997; 46: 707–11

    CAS  Google Scholar 

  80. Laurberg P, Weeke J. Differences in the effects of levothyroxin and Eltroxin [in Danish]. Ugeskr Laeger 1987; 149: 2396–7

    PubMed  CAS  Google Scholar 

  81. Woeber KA, Sobel RJ, Ingbar SH, et al. The peripheral metabolism of triiodothyronine in normal subjects and in patients with hyperthyroidism. J Clin Invest 1970; 49: 643–9

    PubMed  PubMed Central  CAS  Google Scholar 

  82. Shibata H, Hayakawa H, Hirukawa M, et al. Hypersensitivity caused by synthetic thyroid hormones in a hypothyroid patient with Hashimoto’s thyroiditis. Arch Intern Med 1986 Aug; 146(8): 1624–5

    PubMed  CAS  Google Scholar 

  83. Ohmori M, Harada K, Tsuruoka S, et al. Levothyroxine-induced liver dysfunction in a primary hypothyroid patient. Endocr J 1999 Aug; 46(4): 579–83

    PubMed  CAS  Google Scholar 

  84. Cappola AR, Ladenson PW. Hypothyroidism and atherosclerosis. J Clin Endocrinol Metab 2003; 88: 2438–44

    PubMed  CAS  Google Scholar 

  85. Duntas LH. Thyroid disease and lipids. Thyroid 2002; 12: 287–93

    PubMed  CAS  Google Scholar 

  86. Kahaly GJ, Kampmann C, Mohr-Kahaly S. Cardiovascular hemodynamics and exercise tolerance in thyroid disease. Thyroid 2002; 12: 473–81

    PubMed  Google Scholar 

  87. Rennie JA, Bewsher PD, Murchison LE, et al. Coagulation and fibrinolysis in thyroid disease. Acta Haematol 1978; 59: 171–7

    PubMed  CAS  Google Scholar 

  88. Erfurth EM, Ericsson UB, Egervall K, et al. Effect of acute desmopressin and of long-term thyroxine replacement on haemostasis in hypothyroidism. Clin Endocrinol 1995; 42: 373–8

    CAS  Google Scholar 

  89. Ellyin F, Fuh CY, Singh SP, et al. Hypothyroidism with angina pectoris: a clinical dilemma. Postgrad Med 1986; 79: 93–8

    PubMed  CAS  Google Scholar 

  90. Keating Jr FR, Parkin TW, Selby JB, et al. Treatment of heart disease associated with myxedema. Prog Cardiovasc Dis 1961; 3: 364–81

    PubMed  Google Scholar 

  91. Cooper DS, Ridgway EC. Thoughts on prevention of thyroid disease in the United States. Thyroid 2002; 12: 925–9

    PubMed  Google Scholar 

  92. Uzzan B, Campos J, Cucherat M, et al. Effects on bone mass of long term treatment with thyroid hormones: a meta-analysis. J Clin Endocrinol Metab 1996; 81: 4278–89

    PubMed  CAS  Google Scholar 

  93. Faber J, Galloe AM. Changes in bone mass during prolonged subclinical hyperthyroidism due to L-thyroxine treatment: a meta-analysis. Eur J Endocrinol 1994; 130: 350–6

    PubMed  CAS  Google Scholar 

  94. Saravanan P, Chau WF, Roberts N, et al. Psychological well-being in patients on ‘adequate’ doses of l-thyroxine: results of a large, controlled community-based questionnaire study. Clin Endocrinol 2002; 57: 577–85

    CAS  Google Scholar 

  95. Cooper DS. Clinical practice: subclinical hypothyroidism. N Engl J Med 2001; 345: 260–5

    PubMed  CAS  Google Scholar 

  96. Andersen S, Bruun NH, Pedersen KM, et al. Biologic variation is important for interpretation of thyroid function tests. Thyroid 2003; 13: 1069–78

    PubMed  CAS  Google Scholar 

  97. Bunevicius R, Kazanavicius G, Zalinkevicius R, et al. Effects of thyroxine as compared with thyroxine plus triiodothyronine in patients with hypothyroidism. N Engl J Med 1999; 340: 424–9

    PubMed  CAS  Google Scholar 

  98. Bunevicius R, Jakubonien N, Jurkevicius R, et al. Thyroxine vs thyroxine plus triiodothyronine in treatment of hypothyroidism after thyroidectomy for Graves’ disease. Endocrine 2002; 18: 129–33

    PubMed  CAS  Google Scholar 

  99. Kaplan MM, Sarne DH, Schneider AB. In search of the impossible dream? Thyroid hormone replacement therapy that treats all symptoms in all hypothyroid patients. J Clin Endocrinol Metab 2003; 88: 4540–2

    PubMed  CAS  Google Scholar 

  100. Clyde PW, Harari AE, Getka EJ, et al. Combined levothyroxine plus liothyronine compared with levothyroxine alone in primary hypothyroidism: a randomized controlled trial. JAMA 2003; 290: 2952–8

    PubMed  CAS  Google Scholar 

  101. Walsh JP, Shiels L, Lim EM, et al. Combined thyroxine/liothyronine treatment does not improve well-being, quality of life, or cognitive function compared to thyroxine alone: a randomized controlled trial in patients with primary hypothyroidism. J Clin Endocrinol Metab 2003; 88: 4543–50

    PubMed  CAS  Google Scholar 

  102. Sawka AM, Gerstein HC, Marriott MJ, et al. Does a combination regimen of thyroxine (T4) and 3,5,3′-triiodothyronine improve depressive symptoms better than T4 alone in patients with hypothyroidism? Results of a double-blind, randomized, controlled trial. J Clin Endocrinol Metab 2003; 88: 4551–5

    PubMed  CAS  Google Scholar 

  103. Escobar-Morreale HF, del Rey FE, Obregon MJ, et al. Only the combined treatment with thyroxine and triiodothyronine ensures euthyroidism in all tissues of the thyroidectomized rat. Endocrinology 1996; 137: 2490–502

    PubMed  CAS  Google Scholar 

  104. Weeke J, Gundersen HJ. Circadian and 30 minutes variations in serum TSH and thyroid hormones in normal subjects. Acta Endocrinol 1978; 89: 659–72

    PubMed  CAS  Google Scholar 

  105. Laurberg P, Faber J. Subclinical thyroid disease: to treat or not to treat [online]. Hot Thyroidology 2001; 4. Available from URL: http://www.hotthyroidology.com [Accessed 2004 Nov 22]

  106. Surks MI, Ortiz E, Daniels GH, et al. Subclinical thyroid disease: scientific review and guidelines for diagnosis and management. JAMA 2004; 291: 228–38

    PubMed  CAS  Google Scholar 

  107. Kong WM, Sheikh MH, Lumb PJ, et al. A 6-month randomized trial of thyroxine treatment in women with mild subclinical hypothyroidism. Am J Med 2002; 112: 348–54

    PubMed  CAS  Google Scholar 

  108. Jaeschke R, Guyatt G, Gerstein H, et al. Does treatment with L-thyroxine influence health status in middle-aged and older adults with subclinical hypothyroidism? J Gen Intern Med 1996; 11: 744–9

    PubMed  CAS  Google Scholar 

  109. Meier C, Staub JJ, Roth CB, et al. TSH-controlled L-thyroxine therapy reduces cholesterol levels and clinical symptoms in subclinical hypothyroidism: a double blind, placebo-controlled trial. Basel Thyroid Study. J Clin Endocrinol Metab 2001; 86: 4860–6

    PubMed  CAS  Google Scholar 

  110. Cooper DS, Halpern R, Wood LC, et al. L-Thyroxine therapy in subclinical hypothyroidism: a double-blind, placebo-controlled trial. Ann Intern Med 1984; 101: 18–24

    PubMed  CAS  Google Scholar 

  111. Nystrom E, Caidahl K, Fager G, et al. A double-blind cross-over 12-month study of L-thyroxine treatment of women with ‘subclinical’ hypothyroidism. Clin Endocrinol 1988; 29: 63–75

    CAS  Google Scholar 

  112. Col NF, Surks MI, Daniels GH. Subclinical thyroid disease: clinical applications. JAMA 2004; 291: 239–43

    PubMed  CAS  Google Scholar 

Download references

Acknowledgements

No sources of funding were used to assist in the preparation of this review. The authors have no conflicts of interest that are directly relevant to the content of this review.

Author information

Affiliations

  1. Department of Endocrinology and Medicine, Aalborg Hospital, Aarhus University Hospital, Aalborg, Denmark

    Peter Laurberg, Stig Andersen, Inge Büllow Pedersen & Allan Carlé

Authors
  1. Peter Laurberg
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Stig Andersen
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Inge Büllow Pedersen
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Allan Carlé
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Peter Laurberg.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Laurberg, P., Andersen, S., Pedersen, I.B. et al. Hypothyroidism in the Elderly: Pathophysiology, Diagnosis and Treatment. Drugs Aging 22, 23–38 (2005). https://doi.org/10.2165/00002512-200522010-00002

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00002512-200522010-00002

Keywords

  • Thyroid Hormone
  • Hypothyroidism
  • Iodine Deficiency
  • Iodine Intake
  • Subclinical Hypothyroidism